Neos Therapeutics (NEOS) Misses Q4 EPS by 4c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
March 13, 2020 7:46 AM EDTFull year 2019 net revenues increased by 29% and operating loss decreased by $33M
 Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end
NT0502 Phase 1 ascending dose trial initiation planned in 2H20 following top-line PK data
Company to host conference call today at 8:30am ET
DALLAS and FORT WORTH, Texas, March 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the fourth quarter and fiscal... More
